Key clinical point: Higher baseline serum levels of choline, betaine, and phenylacetylglutamine are associated with increased risk for incident lethal prostate cancer.

Major finding: Compared with the patients in the first quartile, the risk for incident lethal prostate cancer was higher in those with higher baseline levels of choline (odds ratio [OR] for third and fourth quartile, 2.37 and 2.19, respectively; P for trend = .005), betaine (OR for third and fourth quartile, 2.13 and 1.86, respectively; P for trend = .11), and phenylacetylglutamine (OR for third and fourth quartile, 2.54 and 2.55, respectively; P for trend = .003).

Study details: A study of 173 patients with lethal prostate cancer and 519 healthy individuals from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening trial.

Disclosures: This study was supported by grants from National Cancer Institute and Prostate Cancer Foundation. The authors held patents and/or received consulting fees/research grants/royalties from various sources.

Source: Reichard CA et al. Cancer Epidemiol Biomarkers Prev. 2021 Oct 28. doi: 10.1158/1055-9965.

Key clinical point: Higher baseline serum levels of choline, betaine, and phenylacetylglutamine are associated with increased risk for incident lethal prostate cancer.

Major finding: Compared with the patients in the first quartile, the risk for incident lethal prostate cancer was higher in those with higher baseline levels of choline (odds ratio [OR] for third and fourth quartile, 2.37 and 2.19, respectively; P for trend = .005), betaine (OR for third and fourth quartile, 2.13 and 1.86, respectively; P for trend = .11), and phenylacetylglutamine (OR for third and fourth quartile, 2.54 and 2.55, respectively; P for trend = .003).

Study details: A study of 173 patients with lethal prostate cancer and 519 healthy individuals from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening trial.

Disclosures: This study was supported by grants from National Cancer Institute and Prostate Cancer Foundation. The authors held patents and/or received consulting fees/research grants/royalties from various sources.

Source: Reichard CA et al. Cancer Epidemiol Biomarkers Prev. 2021 Oct 28. doi: 10.1158/1055-9965.

Key clinical point: Higher baseline serum levels of choline, betaine, and phenylacetylglutamine are associated with increased risk for incident lethal prostate cancer.

Major finding: Compared with the patients in the first quartile, the risk for incident lethal prostate cancer was higher in those with higher baseline levels of choline (odds ratio [OR] for third and fourth quartile, 2.37 and 2.19, respectively; P for trend = .005), betaine (OR for third and fourth quartile, 2.13 and 1.86, respectively; P for trend = .11), and phenylacetylglutamine (OR for third and fourth quartile, 2.54 and 2.55, respectively; P for trend = .003).

Study details: A study of 173 patients with lethal prostate cancer and 519 healthy individuals from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening trial.

Disclosures: This study was supported by grants from National Cancer Institute and Prostate Cancer Foundation. The authors held patents and/or received consulting fees/research grants/royalties from various sources.

Source: Reichard CA et al. Cancer Epidemiol Biomarkers Prev. 2021 Oct 28. doi: 10.1158/1055-9965.

Key clinical point: Radical prostatectomy vs external beam radiotherapy (EBRT) is associated with lower cancer-specific mortality in African American patients with National Comprehensive Cancer Network (NCCN) high-risk and Johns Hopkins University (JH) very high-risk prostate cancer.

Major finding: Radical prostatectomy and EBRT were performed in 39% and 61% of patients, respectively. Radical prostatectomy vs EBRT was associated with lower risk for cancer-specific mortality at 5 years in NCCN high-risk (2.3% vs 3.9%; hazard ratio [HR], 0.52; P = .02) and JH very high-risk patients (3.3% vs 7.4%; HR, 0.42; P = .02).

Study details: A retrospective study of 4,165 NCCN high-risk African American patients with prostate cancer identified from the Surveillance, Epidemiology, and End Results database between 2010 and 2016. Patients were subcategorized into JH high-risk (n=1,944) and very high-risk (n=2,221) groups.

Disclosures: No funding source was identified for this work. The authors declared no conflict of interests.

Source: Hoeh B et al. Prostate. 2021 Oct 18. doi: 10.1002/pros.24253.

Key clinical point: Radical prostatectomy vs external beam radiotherapy (EBRT) is associated with lower cancer-specific mortality in African American patients with National Comprehensive Cancer Network (NCCN) high-risk and Johns Hopkins University (JH) very high-risk prostate cancer.

Major finding: Radical prostatectomy and EBRT were performed in 39% and 61% of patients, respectively. Radical prostatectomy vs EBRT was associated with lower risk for cancer-specific mortality at 5 years in NCCN high-risk (2.3% vs 3.9%; hazard ratio [HR], 0.52; P = .02) and JH very high-risk patients (3.3% vs 7.4%; HR, 0.42; P = .02).

Study details: A retrospective study of 4,165 NCCN high-risk African American patients with prostate cancer identified from the Surveillance, Epidemiology, and End Results database between 2010 and 2016. Patients were subcategorized into JH high-risk (n=1,944) and very high-risk (n=2,221) groups.

Disclosures: No funding source was identified for this work. The authors declared no conflict of interests.

Source: Hoeh B et al. Prostate. 2021 Oct 18. doi: 10.1002/pros.24253.

Key clinical point: Radical prostatectomy vs external beam radiotherapy (EBRT) is associated with lower cancer-specific mortality in African American patients with National Comprehensive Cancer Network (NCCN) high-risk and Johns Hopkins University (JH) very high-risk prostate cancer.

Major finding: Radical prostatectomy and EBRT were performed in 39% and 61% of patients, respectively. Radical prostatectomy vs EBRT was associated with lower risk for cancer-specific mortality at 5 years in NCCN high-risk (2.3% vs 3.9%; hazard ratio [HR], 0.52; P = .02) and JH very high-risk patients (3.3% vs 7.4%; HR, 0.42; P = .02).

Study details: A retrospective study of 4,165 NCCN high-risk African American patients with prostate cancer identified from the Surveillance, Epidemiology, and End Results database between 2010 and 2016. Patients were subcategorized into JH high-risk (n=1,944) and very high-risk (n=2,221) groups.

Disclosures: No funding source was identified for this work. The authors declared no conflict of interests.

Source: Hoeh B et al. Prostate. 2021 Oct 18. doi: 10.1002/pros.24253.

Key clinical point: Significant racial and ethnic disparities are reported in the use of prostate magnetic resonance imaging (MRI) following elevated prostate-specific antigen (PSA) test results.

Major finding: Black patients with PSA levels above 4 ng/mL and 10 ng/mL were 24.1% and 35.0% less likely to undergo subsequent prostate MRI, respectively, compared with White patients. Asian patients with PSA levels higher than 4 ng/mL were 24.1% less likely, and Hispanic patients with PSA levels above 10 ng/mL were 23.4% less likely to undergo subsequent prostate MRI than White patients.

Study details: A cohort study of 794,809 patients aged 40 years and above who received a single PSA result and no prior PSA screening or prostate MRI.

Disclosures: This work was supported by research funding from Harvey L. Neiman Health Policy Institute. Dr. Rosenkrantz reported employment with American Journal of Roentgenology. No other disclosures were reported.

Source: Abashidze N et al. JAMA Network Open. 2021 Nov 8. doi: 10.1001/jamanetworkopen.2021.32388.

Key clinical point: Significant racial and ethnic disparities are reported in the use of prostate magnetic resonance imaging (MRI) following elevated prostate-specific antigen (PSA) test results.

Major finding: Black patients with PSA levels above 4 ng/mL and 10 ng/mL were 24.1% and 35.0% less likely to undergo subsequent prostate MRI, respectively, compared with White patients. Asian patients with PSA levels higher than 4 ng/mL were 24.1% less likely, and Hispanic patients with PSA levels above 10 ng/mL were 23.4% less likely to undergo subsequent prostate MRI than White patients.

Study details: A cohort study of 794,809 patients aged 40 years and above who received a single PSA result and no prior PSA screening or prostate MRI.

Disclosures: This work was supported by research funding from Harvey L. Neiman Health Policy Institute. Dr. Rosenkrantz reported employment with American Journal of Roentgenology. No other disclosures were reported.

Source: Abashidze N et al. JAMA Network Open. 2021 Nov 8. doi: 10.1001/jamanetworkopen.2021.32388.

Key clinical point: Significant racial and ethnic disparities are reported in the use of prostate magnetic resonance imaging (MRI) following elevated prostate-specific antigen (PSA) test results.

Major finding: Black patients with PSA levels above 4 ng/mL and 10 ng/mL were 24.1% and 35.0% less likely to undergo subsequent prostate MRI, respectively, compared with White patients. Asian patients with PSA levels higher than 4 ng/mL were 24.1% less likely, and Hispanic patients with PSA levels above 10 ng/mL were 23.4% less likely to undergo subsequent prostate MRI than White patients.

Study details: A cohort study of 794,809 patients aged 40 years and above who received a single PSA result and no prior PSA screening or prostate MRI.

Disclosures: This work was supported by research funding from Harvey L. Neiman Health Policy Institute. Dr. Rosenkrantz reported employment with American Journal of Roentgenology. No other disclosures were reported.

Source: Abashidze N et al. JAMA Network Open. 2021 Nov 8. doi: 10.1001/jamanetworkopen.2021.32388.

Key clinical point: Prostrate-specific antigen (PSA) testing increased after the 2017 United States Preventive Services Task Force (USPSTF) draft statement for prostate cancer screening.

Major finding: A relative increase of 12.5% was seen in the PSA testing rate during 2016-2019. A relative increase of 10.1%, 12.1%, and 16.2% was seen in men aged 40-54 years, 55-69 years, and 70-89 years. A significantly increasing trend of PSA testing was seen after the release of USPSTF draft in April 2017 (0.30 tests per 100 person-years for each bimonthly period; P < .001).

Study details: This retrospective cohort study of 8,087,565 men aged 40 to 89 years who underwent prostate cancer screening between 2013 and 2019.

Disclosures: This work was funded by National Institutes of Health/National Cancer Institute. The authors received grants, honoraria, and consulting/personal/speaker fees from various sources.

Source: Leapman MS et al. JAMA Oncol. 2021 Nov 11. doi: 10.1001/jamaoncol.2021.5143.

Key clinical point: Prostrate-specific antigen (PSA) testing increased after the 2017 United States Preventive Services Task Force (USPSTF) draft statement for prostate cancer screening.

Major finding: A relative increase of 12.5% was seen in the PSA testing rate during 2016-2019. A relative increase of 10.1%, 12.1%, and 16.2% was seen in men aged 40-54 years, 55-69 years, and 70-89 years. A significantly increasing trend of PSA testing was seen after the release of USPSTF draft in April 2017 (0.30 tests per 100 person-years for each bimonthly period; P < .001).

Study details: This retrospective cohort study of 8,087,565 men aged 40 to 89 years who underwent prostate cancer screening between 2013 and 2019.

Disclosures: This work was funded by National Institutes of Health/National Cancer Institute. The authors received grants, honoraria, and consulting/personal/speaker fees from various sources.

Source: Leapman MS et al. JAMA Oncol. 2021 Nov 11. doi: 10.1001/jamaoncol.2021.5143.

Key clinical point: Prostrate-specific antigen (PSA) testing increased after the 2017 United States Preventive Services Task Force (USPSTF) draft statement for prostate cancer screening.

Major finding: A relative increase of 12.5% was seen in the PSA testing rate during 2016-2019. A relative increase of 10.1%, 12.1%, and 16.2% was seen in men aged 40-54 years, 55-69 years, and 70-89 years. A significantly increasing trend of PSA testing was seen after the release of USPSTF draft in April 2017 (0.30 tests per 100 person-years for each bimonthly period; P < .001).

Study details: This retrospective cohort study of 8,087,565 men aged 40 to 89 years who underwent prostate cancer screening between 2013 and 2019.

Disclosures: This work was funded by National Institutes of Health/National Cancer Institute. The authors received grants, honoraria, and consulting/personal/speaker fees from various sources.

Source: Leapman MS et al. JAMA Oncol. 2021 Nov 11. doi: 10.1001/jamaoncol.2021.5143.

Key clinical point: Enzalutamide improves outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) in a prospective real-world study.

Major finding: The median time to treatment failure in chemotherapy and abiraterone-naïve patients was 12.9 months and those who were previously treated with chemotherapy and were abiraterone naïve was 8.4 months.

Study details: A prospective, observational PREMISE study of 1,732 patients with mCRPC who received enzalutamide.

Disclosures: This study was sponsored by Astellas Pharma Inc. The authors received honoraria, travel funds, grants, consulting/personal fees, and financial and nonfinancial support from various sources. Some authors reported being employed by an organization/foundation that receives funding from various private and public sector sources.

Source: Payne H et al. Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33845.

Key clinical point: Enzalutamide improves outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) in a prospective real-world study.

Major finding: The median time to treatment failure in chemotherapy and abiraterone-naïve patients was 12.9 months and those who were previously treated with chemotherapy and were abiraterone naïve was 8.4 months.

Study details: A prospective, observational PREMISE study of 1,732 patients with mCRPC who received enzalutamide.

Disclosures: This study was sponsored by Astellas Pharma Inc. The authors received honoraria, travel funds, grants, consulting/personal fees, and financial and nonfinancial support from various sources. Some authors reported being employed by an organization/foundation that receives funding from various private and public sector sources.

Source: Payne H et al. Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33845.

Key clinical point: Enzalutamide improves outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) in a prospective real-world study.

Major finding: The median time to treatment failure in chemotherapy and abiraterone-naïve patients was 12.9 months and those who were previously treated with chemotherapy and were abiraterone naïve was 8.4 months.

Study details: A prospective, observational PREMISE study of 1,732 patients with mCRPC who received enzalutamide.

Disclosures: This study was sponsored by Astellas Pharma Inc. The authors received honoraria, travel funds, grants, consulting/personal fees, and financial and nonfinancial support from various sources. Some authors reported being employed by an organization/foundation that receives funding from various private and public sector sources.

Source: Payne H et al. Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33845.

Key clinical point: Salvage low-dose-rate (LDR) prostate brachytherapy shows good survival in patients with low-/intermediate-risk prostate cancer who had local failure after external beam radiotherapy (EBRT).

Major finding: The median follow-up was 6.7 years. At 10 years, the overall survival rate was 70%, disease-free survival rate was 33%, and disease-specific survival rate was 70%. Local-, distant-, and biochemical failure rates were 5%, 19%, and 46%, respectively.

Study details: A phase 2 study of 100 patients with low-/intermediate-risk prostate cancer who received salvage LDR prostate brachytherapy for local failure after EBRT.

Disclosures: This work was supported by National Cancer Institute.

Source: Crook J et al. Int J Radiat Oncol Biol Phys. 2021 Nov 2. doi: 10.1016/j.ijrobp.2021.10.138.

Key clinical point: Salvage low-dose-rate (LDR) prostate brachytherapy shows good survival in patients with low-/intermediate-risk prostate cancer who had local failure after external beam radiotherapy (EBRT).

Major finding: The median follow-up was 6.7 years. At 10 years, the overall survival rate was 70%, disease-free survival rate was 33%, and disease-specific survival rate was 70%. Local-, distant-, and biochemical failure rates were 5%, 19%, and 46%, respectively.

Study details: A phase 2 study of 100 patients with low-/intermediate-risk prostate cancer who received salvage LDR prostate brachytherapy for local failure after EBRT.

Disclosures: This work was supported by National Cancer Institute.

Source: Crook J et al. Int J Radiat Oncol Biol Phys. 2021 Nov 2. doi: 10.1016/j.ijrobp.2021.10.138.

Key clinical point: Salvage low-dose-rate (LDR) prostate brachytherapy shows good survival in patients with low-/intermediate-risk prostate cancer who had local failure after external beam radiotherapy (EBRT).

Major finding: The median follow-up was 6.7 years. At 10 years, the overall survival rate was 70%, disease-free survival rate was 33%, and disease-specific survival rate was 70%. Local-, distant-, and biochemical failure rates were 5%, 19%, and 46%, respectively.

Study details: A phase 2 study of 100 patients with low-/intermediate-risk prostate cancer who received salvage LDR prostate brachytherapy for local failure after EBRT.

Disclosures: This work was supported by National Cancer Institute.

Source: Crook J et al. Int J Radiat Oncol Biol Phys. 2021 Nov 2. doi: 10.1016/j.ijrobp.2021.10.138.

Key clinical point: After the first screening round, carriers of MSH2 and MSH6 pathogenic variants had a higher incidence of prostate cancer vs age-matched noncarrier controls.

Major finding: Men with MSH2 (P = .011) and MSH6 (P = .034) carriers showed a higher incidence of prostate cancer (prostate-specific antigen [PSA] threshold of 3 ng/mL or higher) vs noncarrier individuals. The overall positive predictive value of biopsy using a PSA threshold of 3 ng/mL was 51.4%.

Study details: An international, prospective IMPACT study of 644 men without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene and 184 age-matched male controls without a familial pathogenic variant in these genes.

Disclosures: This study was supported by Cancer Research UK, the Ronald and Rita McAulay Foundation, and others. The authors received honoraria and/or speaker fees and reported owning patents licensed to and stocks in Arctic Partners.

Source: Bancroft EK et al. Lancet Oncol. 2021 Oct 19. doi: 10.1016/S1470-2045(21)00522-2.

Key clinical point: After the first screening round, carriers of MSH2 and MSH6 pathogenic variants had a higher incidence of prostate cancer vs age-matched noncarrier controls.

Major finding: Men with MSH2 (P = .011) and MSH6 (P = .034) carriers showed a higher incidence of prostate cancer (prostate-specific antigen [PSA] threshold of 3 ng/mL or higher) vs noncarrier individuals. The overall positive predictive value of biopsy using a PSA threshold of 3 ng/mL was 51.4%.

Study details: An international, prospective IMPACT study of 644 men without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene and 184 age-matched male controls without a familial pathogenic variant in these genes.

Disclosures: This study was supported by Cancer Research UK, the Ronald and Rita McAulay Foundation, and others. The authors received honoraria and/or speaker fees and reported owning patents licensed to and stocks in Arctic Partners.

Source: Bancroft EK et al. Lancet Oncol. 2021 Oct 19. doi: 10.1016/S1470-2045(21)00522-2.

Key clinical point: After the first screening round, carriers of MSH2 and MSH6 pathogenic variants had a higher incidence of prostate cancer vs age-matched noncarrier controls.

Major finding: Men with MSH2 (P = .011) and MSH6 (P = .034) carriers showed a higher incidence of prostate cancer (prostate-specific antigen [PSA] threshold of 3 ng/mL or higher) vs noncarrier individuals. The overall positive predictive value of biopsy using a PSA threshold of 3 ng/mL was 51.4%.

Study details: An international, prospective IMPACT study of 644 men without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene and 184 age-matched male controls without a familial pathogenic variant in these genes.

Disclosures: This study was supported by Cancer Research UK, the Ronald and Rita McAulay Foundation, and others. The authors received honoraria and/or speaker fees and reported owning patents licensed to and stocks in Arctic Partners.

Source: Bancroft EK et al. Lancet Oncol. 2021 Oct 19. doi: 10.1016/S1470-2045(21)00522-2.

Key clinical point: The risk for grade 3-4 (G3-4) neutropenia and febrile neutropenia (FN) is higher with FOLFOXIRI/bevacizumab vs doublets/bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC), with the risk being higher in older females, who may benefit with prophylactic use of granulocyte colony-stimulating factor.

Major finding: The incidence of G3-4 neutropenia (51% vs 21%; P < .001), FN (8% vs 4%; P = .02), and high-risk FN (3% vs 1%; P = .015) was significantly higher with FOLFOXIRI/bevacizumab vs doublet/bevacizumab, mostly during the first cycles. The risk for G3-4 neutropenia was significantly higher among older patients (P = .01) and females (P < .001).

Study details: This pooled analysis included 1,155 patients with untreated mCRC from TRIBE1 and TRIBE 2 phase 3 trials, of which 568 patients received FOLFOXIRI/bevacizumab and 587 received doublet/bevacizumab (FOLFIRI/bevacizumab; n=254 or FOLFOX/bevacizumab; n=335).

Disclosures: This study was supported by GONO and ARCO Foundations. Some of the authors declared receiving honoraria, travel grant, research funding, speakers’ bureau, and/or consulting or advisory role for various sources.

Source: Rossini D et al. ESMO Open. 2021 Oct 21. doi: 10.1016/j.esmoop.2021.100293.

Key clinical point: The risk for grade 3-4 (G3-4) neutropenia and febrile neutropenia (FN) is higher with FOLFOXIRI/bevacizumab vs doublets/bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC), with the risk being higher in older females, who may benefit with prophylactic use of granulocyte colony-stimulating factor.

Major finding: The incidence of G3-4 neutropenia (51% vs 21%; P < .001), FN (8% vs 4%; P = .02), and high-risk FN (3% vs 1%; P = .015) was significantly higher with FOLFOXIRI/bevacizumab vs doublet/bevacizumab, mostly during the first cycles. The risk for G3-4 neutropenia was significantly higher among older patients (P = .01) and females (P < .001).

Study details: This pooled analysis included 1,155 patients with untreated mCRC from TRIBE1 and TRIBE 2 phase 3 trials, of which 568 patients received FOLFOXIRI/bevacizumab and 587 received doublet/bevacizumab (FOLFIRI/bevacizumab; n=254 or FOLFOX/bevacizumab; n=335).

Disclosures: This study was supported by GONO and ARCO Foundations. Some of the authors declared receiving honoraria, travel grant, research funding, speakers’ bureau, and/or consulting or advisory role for various sources.

Source: Rossini D et al. ESMO Open. 2021 Oct 21. doi: 10.1016/j.esmoop.2021.100293.

Key clinical point: The risk for grade 3-4 (G3-4) neutropenia and febrile neutropenia (FN) is higher with FOLFOXIRI/bevacizumab vs doublets/bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC), with the risk being higher in older females, who may benefit with prophylactic use of granulocyte colony-stimulating factor.

Major finding: The incidence of G3-4 neutropenia (51% vs 21%; P < .001), FN (8% vs 4%; P = .02), and high-risk FN (3% vs 1%; P = .015) was significantly higher with FOLFOXIRI/bevacizumab vs doublet/bevacizumab, mostly during the first cycles. The risk for G3-4 neutropenia was significantly higher among older patients (P = .01) and females (P < .001).

Study details: This pooled analysis included 1,155 patients with untreated mCRC from TRIBE1 and TRIBE 2 phase 3 trials, of which 568 patients received FOLFOXIRI/bevacizumab and 587 received doublet/bevacizumab (FOLFIRI/bevacizumab; n=254 or FOLFOX/bevacizumab; n=335).

Disclosures: This study was supported by GONO and ARCO Foundations. Some of the authors declared receiving honoraria, travel grant, research funding, speakers’ bureau, and/or consulting or advisory role for various sources.

Source: Rossini D et al. ESMO Open. 2021 Oct 21. doi: 10.1016/j.esmoop.2021.100293.

Key clinical point: Women who underwent adenoma removal appear to be at a higher risk for colorectal cancer (CRC) incidence and CRC-related deaths, highlighting the need for sex-specific surveillance after adenoma removal.

Major finding: Compared with general population, CRC incidence was higher in women (standardized incidence ratios [SIR], 1.64; 95% CI, 1.54-1.74) than in men (SIR, 1.12; 95% CI, 1.05-1.19) who had adenomas removed. CRC mortality increased in women (standardized incidence-based mortality ratios [SMR], 1.13; 95% CI, 1.02-1.26) and reduced in men (SMR, 0.79; 95% CI, 0.71-0.89) who underwent adenoma removal compared with general population.

Study details: Findings are from a cohort study of 40,293 individuals who had their adenomas removed.

Disclosures: This work was supported by grants from Norwegian Research Council and Norwegian Cancer Society. The authors declared no conflict of interests.

Source: Jodal HC et al. Aliment Pharmacol Ther. 2021 Oct 30. doi: 10.1111/apt.16686.

Key clinical point: Women who underwent adenoma removal appear to be at a higher risk for colorectal cancer (CRC) incidence and CRC-related deaths, highlighting the need for sex-specific surveillance after adenoma removal.

Major finding: Compared with general population, CRC incidence was higher in women (standardized incidence ratios [SIR], 1.64; 95% CI, 1.54-1.74) than in men (SIR, 1.12; 95% CI, 1.05-1.19) who had adenomas removed. CRC mortality increased in women (standardized incidence-based mortality ratios [SMR], 1.13; 95% CI, 1.02-1.26) and reduced in men (SMR, 0.79; 95% CI, 0.71-0.89) who underwent adenoma removal compared with general population.

Study details: Findings are from a cohort study of 40,293 individuals who had their adenomas removed.

Disclosures: This work was supported by grants from Norwegian Research Council and Norwegian Cancer Society. The authors declared no conflict of interests.

Source: Jodal HC et al. Aliment Pharmacol Ther. 2021 Oct 30. doi: 10.1111/apt.16686.

Key clinical point: Women who underwent adenoma removal appear to be at a higher risk for colorectal cancer (CRC) incidence and CRC-related deaths, highlighting the need for sex-specific surveillance after adenoma removal.

Major finding: Compared with general population, CRC incidence was higher in women (standardized incidence ratios [SIR], 1.64; 95% CI, 1.54-1.74) than in men (SIR, 1.12; 95% CI, 1.05-1.19) who had adenomas removed. CRC mortality increased in women (standardized incidence-based mortality ratios [SMR], 1.13; 95% CI, 1.02-1.26) and reduced in men (SMR, 0.79; 95% CI, 0.71-0.89) who underwent adenoma removal compared with general population.

Study details: Findings are from a cohort study of 40,293 individuals who had their adenomas removed.

Disclosures: This work was supported by grants from Norwegian Research Council and Norwegian Cancer Society. The authors declared no conflict of interests.

Source: Jodal HC et al. Aliment Pharmacol Ther. 2021 Oct 30. doi: 10.1111/apt.16686.

Key clinical point: Pre-operative sarcopenia predicted shorter disease-free survival (DFS), overall survival (OS), and recurrence of the liver in patients with lower advanced rectal cancer receiving preoperative adjuvant chemoradiotherapy (CRT).

Major finding: Post-CRT sarcopenia was an independent prognostic factor for shorter DFS (hazard ratio [HR], 2.01; P = .049), OS (HR, 1.76; P = .036), and recurrence in the liver (HR, 3.01; P = .025).

Study details: Findings are from a retrospective analysis of 234 patients with cT3-T4 anyN M0 lower rectal cancer who underwent CRT (5-fluorouracil-based oral chemotherapy and long course radiation) followed by radical surgery.

Disclosures: This study was supported by Japan Society for the Promotion of Science and Japan Agency for Medical Research and Development. The authors declared no conflict of interests.

Source: Abe S et al. Int J Clin Oncol. 2021 Nov 6. doi: 10.1007/s10147-021-02062-z.

Key clinical point: Pre-operative sarcopenia predicted shorter disease-free survival (DFS), overall survival (OS), and recurrence of the liver in patients with lower advanced rectal cancer receiving preoperative adjuvant chemoradiotherapy (CRT).

Major finding: Post-CRT sarcopenia was an independent prognostic factor for shorter DFS (hazard ratio [HR], 2.01; P = .049), OS (HR, 1.76; P = .036), and recurrence in the liver (HR, 3.01; P = .025).

Study details: Findings are from a retrospective analysis of 234 patients with cT3-T4 anyN M0 lower rectal cancer who underwent CRT (5-fluorouracil-based oral chemotherapy and long course radiation) followed by radical surgery.

Disclosures: This study was supported by Japan Society for the Promotion of Science and Japan Agency for Medical Research and Development. The authors declared no conflict of interests.

Source: Abe S et al. Int J Clin Oncol. 2021 Nov 6. doi: 10.1007/s10147-021-02062-z.

Key clinical point: Pre-operative sarcopenia predicted shorter disease-free survival (DFS), overall survival (OS), and recurrence of the liver in patients with lower advanced rectal cancer receiving preoperative adjuvant chemoradiotherapy (CRT).

Major finding: Post-CRT sarcopenia was an independent prognostic factor for shorter DFS (hazard ratio [HR], 2.01; P = .049), OS (HR, 1.76; P = .036), and recurrence in the liver (HR, 3.01; P = .025).

Study details: Findings are from a retrospective analysis of 234 patients with cT3-T4 anyN M0 lower rectal cancer who underwent CRT (5-fluorouracil-based oral chemotherapy and long course radiation) followed by radical surgery.

Disclosures: This study was supported by Japan Society for the Promotion of Science and Japan Agency for Medical Research and Development. The authors declared no conflict of interests.

Source: Abe S et al. Int J Clin Oncol. 2021 Nov 6. doi: 10.1007/s10147-021-02062-z.